Kanser tedavisi s\u00fcrecinde s\u0131k\u00e7a g\u00f6z ard\u0131 edilen ancak kritik \u00f6nem ta\u015f\u0131yan bir komplikasyon olan sarkopeni, kas k\u00fctlesi ve kas g\u00fcc\u00fcn\u00fcn giderek azalmas\u0131yla karakterize edilir. Son y\u0131llarda yap\u0131lan ara\u015ft\u0131rmalar, sarkopeninin meme kanseri tan\u0131s\u0131 konan kad\u0131nlar\u0131n tedavi etkinli\u011fini olumsuz etkiledi\u011fini, ya\u015fam kalitesini d\u00fc\u015f\u00fcrd\u00fc\u011f\u00fcn\u00fc ve hastalar\u0131n k\u0131r\u0131lganl\u0131k d\u00fczeyini art\u0131rd\u0131\u011f\u0131n\u0131 ortaya koymu\u015ftur. BMC Cancer dergisinde yay\u0131mlanan \u00f6nc\u00fc bir \u00e7al\u0131\u015fmada, bu hassas hasta grubunda sarkopeni riskini tespit i\u00e7in kullan\u0131lan \u00fc\u00e7 farkl\u0131 tarama arac\u0131n\u0131n kar\u015f\u0131la\u015ft\u0131rmal\u0131 de\u011ferlendirmesi yap\u0131lm\u0131\u015ft\u0131r. \u00c7al\u0131\u015fma, mevcut yakla\u015f\u0131mlara meydan okuyarak klinik uygulamalarda yeni kap\u0131lar aralam\u0131\u015ft\u0131r.<\/p>\n
Sarkopeni, kademeli ve genellikle belirti vermeden ilerleyen bir s\u00fcre\u00e7 olmas\u0131 nedeniyle sinsi bir hastal\u0131k olarak tan\u0131mlanabilir. Meme kanseri hastalar\u0131nda ise, kanserin metabolik ve fizyolojik stresleri ile tedavi s\u00fcrecinin yan etkileri bu kas erimesini h\u0131zland\u0131rabilmektedir. Bu sebeple, sarkopeni riskinin erken d\u00f6nemde tespiti i\u00e7in pratik ve g\u00fcvenilir tarama ara\u00e7lar\u0131na ihtiya\u00e7 vard\u0131r. B\u00f6ylece zaman\u0131nda m\u00fcdahalelerle kas sa\u011fl\u0131\u011f\u0131 korunabilir, hastalar\u0131n genel prognozu iyile\u015ftirilebilir. S\u00f6z konusu \u00e7al\u0131\u015fmada, SARC-F, SARC-CalF ve BV\u0130 (BMI) uyarlanm\u0131\u015f SARC-CalF olmak \u00fczere \u00fc\u00e7 farkl\u0131 tarama arac\u0131, yeni meme kanseri tan\u0131s\u0131 alan kad\u0131nlarda sarkopeni riskini belirlemede kar\u015f\u0131la\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r.<\/p>\n
\u00c7al\u0131\u015fmaya, tan\u0131 sonras\u0131 ilk bir y\u0131l i\u00e7erisinde olan ve ortalama ya\u015f\u0131 yakla\u015f\u0131k 55 y\u0131l olan 168 kad\u0131n dahil edilmi\u015ftir. Sarkopeni tan\u0131m\u0131, Avrupa Ya\u015fl\u0131larda Sarkopeni \u00c7al\u0131\u015fma Grubu\u2019nun g\u00fcncel kriterleri (EWGSOP2) esas al\u0131narak yap\u0131lm\u0131\u015ft\u0131r. Bu kriterler, el kavrama kuvveti gibi kas g\u00fcc\u00fc \u00f6l\u00e7\u00fcmleri ile \u00e7ift enerjili X-\u0131\u015f\u0131n\u0131 absorbtiometri (DXA) kullan\u0131larak elde edilen \u00fcst ekstremite kas k\u00fctlesi indeksinin birle\u015ftirilmesini i\u00e7ermektedir. Bu sayede tan\u0131, sa\u011flam objektif verilere dayand\u0131r\u0131lm\u0131\u015ft\u0131r.<\/p>\n
Analiz sonu\u00e7lar\u0131, kullan\u0131lan \u00fc\u00e7 ara\u00e7 aras\u0131nda sarkopeni riskinin saptanmas\u0131 a\u00e7\u0131s\u0131ndan belirgin farkl\u0131l\u0131klar g\u00f6stermi\u015ftir. SARC-F arac\u0131, h\u0131zl\u0131 ve kolay uygulanabilen bir anket bazl\u0131 de\u011ferlendirme olmas\u0131na ra\u011fmen sadece kat\u0131l\u0131mc\u0131lar\u0131n yakla\u015f\u0131k %10\u2019unda sarkopeni riski saptayabilmi\u015ftir. Buna kar\u015f\u0131n, bald\u0131r \u00e7evresi \u00f6l\u00e7\u00fcm\u00fcn\u00fc de i\u00e7eren SARC-CalF, riskli hasta oran\u0131n\u0131 \u00fc\u00e7te bire \u00e7\u0131kararak %36,6\u2019ya y\u00fckseltmi\u015ftir. BV\u0130 dikkate al\u0131narak ayarlanm\u0131\u015f SARC-CalF ise, risk tahmininde SARC-CalF ile SARC-F aras\u0131nda kalan ancak tan\u0131 do\u011frulu\u011fu a\u00e7\u0131s\u0131ndan zay\u0131f performans sergileyen bir sonu\u00e7 vermi\u015ftir.<\/p>\n
EWGSOP2 kriterleriyle kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, SARC-CalF arac\u0131 en ba\u015far\u0131l\u0131 tarama metodu olarak \u00f6ne \u00e7\u0131km\u0131\u015ft\u0131r ve al\u0131c\u0131 i\u015flem karakteristik e\u011frisi (AUC) 0,79 olarak bildirilmi\u015ftir. Bu, iyi bir ay\u0131rt edici performansa i\u015faret ederken, SARC-F\u2019in yakla\u015f\u0131k 0,55 ve BV\u0130 uyarlanm\u0131\u015f SARC-CalF\u2019nin 0,52 AUC de\u011ferleri \u015fans sonucu ile kar\u015f\u0131la\u015ft\u0131r\u0131labilecek d\u00fczeyde d\u00fc\u015f\u00fck kalm\u0131\u015ft\u0131r. Ancak SARC-CalF\u2019nin duyarl\u0131l\u0131\u011f\u0131 %42,8 olarak bulunmu\u015f, dolay\u0131s\u0131yla bu ara\u00e7 tek ba\u015f\u0131na kullan\u0131ld\u0131\u011f\u0131nda sarkopeni vakalar\u0131n\u0131n yar\u0131s\u0131ndan fazlas\u0131n\u0131n atlanabilece\u011fini g\u00f6stermi\u015ftir.<\/p>\n
Spesifiklik de\u011ferleri ise farkl\u0131 bir tablo \u00e7izmi\u015ftir. Sarkopeni olmayan hastalar\u0131 do\u011fru bir \u015fekilde saptamada SARC-CalF %92\u2019nin \u00fczerinde y\u00fcksek bir y\u00fczdelik oran yakalam\u0131\u015ft\u0131r. Bu da gereksiz ileri tetkiklerin \u00f6n\u00fcne ge\u00e7erek, hastalar\u0131n psikolojik y\u00fck ve sa\u011fl\u0131k sistemine maliyet a\u00e7\u0131s\u0131ndan \u00f6nemli avantaj sa\u011flam\u0131\u015ft\u0131r. \u00d6te yandan BMI uyarlanm\u0131\u015f SARC-CalF\u2019nin spesifikli\u011fi %63 civar\u0131nda kalm\u0131\u015f ve bu durum, olas\u0131 yanl\u0131\u015f pozitifleri art\u0131rarak g\u00fcvenilirli\u011fini azaltm\u0131\u015ft\u0131r.<\/p>\n
\u00c7al\u0131\u015fma, sarkopeni taramas\u0131nda var olan denge sorununu g\u00f6zler \u00f6n\u00fcne sermektedir. Bald\u0131r \u00e7evresi \u00f6l\u00e7\u00fcm\u00fcn\u00fcn entegrasyonu SARC-F\u2019in \u00f6ng\u00f6r\u00fc g\u00fcc\u00fcn\u00fc \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131r\u0131rken, v\u00fccut k\u00fctle endeksine g\u00f6re ayarlama yapman\u0131n, meme kanserli hastalar\u0131n karma\u015f\u0131k ve de\u011fi\u015fken v\u00fccut kompozisyonlar\u0131 nedeniyle do\u011frulu\u011fu azaltt\u0131\u011f\u0131n\u0131 ortaya koymu\u015ftur. Kanser hastalar\u0131nda kas kitlesindeki erime, ya\u011f da\u011f\u0131l\u0131m\u0131 ve hastal\u0131\u011fa \u00f6zg\u00fc patolojik s\u00fcre\u00e7ler aras\u0131ndaki etkile\u015fim, basit tarama protokollerinin yetersiz kalmas\u0131na neden olmaktad\u0131r.<\/p>\n
Klinik a\u00e7\u0131dan ele al\u0131nd\u0131\u011f\u0131nda, meme kanseri hastalar\u0131n\u0131n ya\u015flar\u0131, tedavi modaliteleri, e\u015flik eden hastal\u0131klar\u0131 ve ya\u015fam \u015fekilleri a\u00e7\u0131s\u0131ndan heterojen olduklar\u0131 unutulmamal\u0131d\u0131r. Yetersiz duyarl\u0131l\u0131\u011fa sahip bir tarama arac\u0131, tedavinin etkilerini engelleyebilecek sarkopeni vakalar\u0131n\u0131n g\u00f6zden ka\u00e7mas\u0131na sebep olurken, a\u015f\u0131r\u0131 hassas metotlar da sa\u011fl\u0131k hizmetleri kaynaklar\u0131n\u0131 a\u015f\u0131r\u0131 t\u00fcketebilir. Bu nedenle, ara\u015ft\u0131rma ekibi pragmatik bir yakla\u015f\u0131m benimsenmesi gerekti\u011fini \u00f6nermektedir. SARC-CalF, g\u00f6receli olarak daha ba\u015far\u0131l\u0131 olsa da, daha kapsaml\u0131 de\u011ferlendirme protokollerinin geli\u015ftirilmesi elzemdir. Bu, biyokimyasal belirte\u00e7lerin, ileri g\u00f6r\u00fcnt\u00fcleme tekniklerinin ve fonksiyonel performans testlerinin entegrasyonunu i\u00e7erebilir.<\/p>\n
Meme kanserinin, sitokin profilleri, hormonal de\u011fi\u015fiklikler ve sitotoksik tedavilerin etkisiyle olu\u015fturdu\u011fu katabolik ortam, evrensel sarkopeni tarama ara\u00e7lar\u0131n\u0131n bu hasta grubunda yetersiz kalmas\u0131na neden olmaktad\u0131r. Bu da \u00f6zel hasta pop\u00fclasyonlar\u0131 i\u00e7in yeni biyobelirte\u00e7lerin geli\u015ftirilmesi ve dijital sa\u011fl\u0131k teknolojilerinin kullan\u0131m\u0131yla erken tan\u0131n\u0131n art\u0131r\u0131lmas\u0131 y\u00f6n\u00fcnde ara\u015ft\u0131rmalar\u0131 te\u015fvik etmektedir.<\/p>\n
\u00c7al\u0131\u015fma ayn\u0131 zamanda kanser alan\u0131nda disiplinleraras\u0131 i\u015f birli\u011finin \u00f6nemini vurgulamaktad\u0131r. Onkologlar, geriatristler, fizyoterapistler ve beslenme uzmanlar\u0131n\u0131n bir araya gelerek, sarkopeninin multifakt\u00f6ryel nedenlerini hedefleyen, kapsaml\u0131 ve ge\u00e7erlili\u011fi kan\u0131tlanm\u0131\u015f tarama paradigmlar\u0131 geli\u015ftirmeleri gerekmektedir. Diren\u00e7 antrenman\u0131, beslenme destekleri ve kas anabolizmas\u0131n\u0131 hedefleyen farmakolojik yakla\u015f\u0131mlar gibi m\u00fcdahalelerin etkinli\u011finin g\u00f6sterilmesine y\u00f6nelik \u00e7al\u0131\u015fmalar\u0131n da artt\u0131r\u0131lmas\u0131 \u00f6nerilmektedir.<\/p>\n
Bununla birlikte, ara\u015ft\u0131rman\u0131n k\u00fc\u00e7\u00fck \u00f6rneklem hacmi ve kesitsel yap\u0131s\u0131, farkl\u0131 etnik gruplar ve tedavi \u015fekillerini i\u00e7eren uzun d\u00f6nem \u00e7al\u0131\u015fmalarla desteklenmesini gerektirmektedir. Bu sayede sarkopeni riskinin meme kanseri bak\u0131m s\u00fcreci boyunca nas\u0131l de\u011fi\u015fti\u011fi, hasta stratifikasyonu ve kaynak optimizasyonu a\u00e7\u0131s\u0131ndan daha iyi anla\u015f\u0131labilecektir.<\/p>\n
Sonu\u00e7 olarak, bu detayl\u0131 kar\u015f\u0131la\u015ft\u0131rmal\u0131 analiz, meme kanseri hastalar\u0131nda sarkopeninin zorluklar\u0131n\u0131 daha iyi tan\u0131mlamaya \u00f6nemli bir katk\u0131 sa\u011flamaktad\u0131r. SARC-CalF, mevcut basit tarama y\u00f6ntemleri aras\u0131nda en uygun se\u00e7enek olmakla birlikte, duyarl\u0131l\u0131k a\u00e7\u0131s\u0131ndan s\u0131n\u0131rlamalar ta\u015f\u0131maktad\u0131r. Sarkopeninin kanser biyolojisi ve hastal\u0131k sonras\u0131 ya\u015fam aras\u0131ndaki karma\u015f\u0131k ba\u011flar\u0131n ayd\u0131nlat\u0131lmas\u0131yla, onsuz care uygulamalar\u0131na entegre edilecek hassas ve pratik tarama metotlar\u0131n\u0131n geli\u015ftirilmesi ka\u00e7\u0131n\u0131lmazd\u0131r. Bu ilerlemeler, d\u00fcnya \u00e7ap\u0131nda say\u0131s\u0131z kad\u0131n\u0131n fonksiyonel sa\u011fl\u0131\u011f\u0131 ve ya\u015fam kalitesine anlaml\u0131 iyile\u015ftirmeler getirebilir.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Web References<\/strong>: Doi Referans<\/strong>: Resim Credits<\/strong>: Anahtar Kelimeler<\/strong>: Kanser tedavisi s\u00fcrecinde s\u0131k\u00e7a g\u00f6z ard\u0131 edilen ancak kritik \u00f6nem ta\u015f\u0131yan bir komplikasyon olan sarkopeni, kas k\u00fctlesi ve kas g\u00fcc\u00fcn\u00fcn giderek azalmas\u0131yla karakterize edilir. Son y\u0131llarda yap\u0131lan ara\u015ft\u0131rmalar, sarkopeninin meme kanseri tan\u0131s\u0131 konan kad\u0131nlar\u0131n tedavi etkinli\u011fini olumsuz etkiledi\u011fini, ya\u015fam kalitesini d\u00fc\u015f\u00fcrd\u00fc\u011f\u00fcn\u00fc ve hastalar\u0131n k\u0131r\u0131lganl\u0131k d\u00fczeyini art\u0131rd\u0131\u011f\u0131n\u0131 ortaya koymu\u015ftur. BMC Cancer dergisinde yay\u0131mlanan \u00f6nc\u00fc bir \u00e7al\u0131\u015fmada,…<\/p>\n","protected":false},"author":1,"featured_media":5190,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[6370,6367,6366,6369,6368],"tmauthors":[],"class_list":{"0":"post-5189","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-ewgsop2-kriterlerine-gore-sarkopeni-degerlendirmesi","9":"tag-meme-kanseri-tedavisinde-sarkopeni-tespiti","10":"tag-meme-kanserinde-sarkopeni-risk-olcum-araclari","11":"tag-sarc-f-ve-sarc-calf-meme-kanseri-hastalarinda","12":"tag-sarkopeni-tarama-yontemleri-karsilastirmasi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/05\/Meme-Kanserinde-Sarkopeni-Risk-Olcum-Araclari-Karsilastirmasi-1746715491.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=5189"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5189\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/5190"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=5189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=5189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=5189"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=5189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nMeme kanseri tan\u0131s\u0131 alan kad\u0131nlarda sarkopeni riskinin de\u011ferlendirilmesi amac\u0131yla kullan\u0131lan tarama ara\u00e7lar\u0131n\u0131n kar\u015f\u0131la\u015ft\u0131rmal\u0131 analizi.<\/p>\n
\nRisk of sarcopenia in women with breast cancer: a comparative analysis of screening tools<\/p>\n
\nhttps:\/\/doi.org\/10.1186\/s12885-025-14062-7<\/p>\n
\nhttps:\/\/doi.org\/10.1186\/s12885-025-14062-7<\/p>\n
\nScienmag.com<\/p>\n
\nmeme kanseri, sarkopeni, kas k\u00fctlesi azalmas\u0131, SARC-F, SARC-CalF, BMI uyarlamas\u0131, tarama ara\u00e7lar\u0131, kas g\u00fcc\u00fc, DXA, erken tan\u0131, klinik uygulama, onkoloji rehabilitasyonu, kas sa\u011fl\u0131\u011f\u0131<\/p>\n","protected":false},"excerpt":{"rendered":"